Can-Fite BioPharma Ltd.
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
CANF | TA
Overview
Corporate Details
- ISIN(s):
- IL0010944739 (+2 more)
- LEI:
- 549300ZLRH6GSBOHFZ59
- Country:
- Israel
- Address:
- PO BOX 7537, 4917000 PETACH-TIKVA
- Website:
- https://www.canfite.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated pharmaceutical discovery and clinical development capabilities. The company is advancing a pipeline of proprietary, orally available small-molecule drug candidates to treat oncology, inflammatory, and metabolic diseases. Can-Fite's platform technology utilizes the A3 adenosine receptor (A3AR) as a therapeutic target. This receptor is highly expressed in pathological cells, allowing the company's compounds to selectively bind to it, triggering anti-cancer and anti-inflammatory effects through the de-regulation of key signal transduction pathways.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-15 15:59 |
Foreign Filer Report
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cir…
|
English | 217.9 KB | ||
| 2025-09-15 15:59 |
Foreign Filer Report
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cir…
|
English | 36.7 KB | ||
| 2025-09-09 02:37 |
Registration Form
Other Report or Announcement
|
English | 530.8 KB | ||
| 2025-09-09 02:37 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.5 KB | ||
| 2025-09-08 19:43 |
Registration Form
Other Report or Announcement
|
English | 454.4 KB | ||
| 2025-09-08 19:43 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.4 KB | ||
| 2025-08-28 17:33 |
Foreign Filer Report
Financial results for the six months ended June 30, 2025 and updates on drug de…
|
English | 339.1 KB | ||
| 2025-08-28 17:33 |
Foreign Filer Report
Financial results for the six months ended June 30, 2025 and updates on drug de…
|
English | 36.8 KB | ||
| 2025-07-30 16:00 |
Foreign Filer Report
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% …
|
English | 144.2 KB | ||
| 2025-07-30 16:00 |
Foreign Filer Report
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% …
|
English | 36.8 KB | ||
| 2025-07-29 19:10 |
Prospectus
Prospectus Filed pursuant to Rule 424(b)(4)
|
English | 455.7 KB | ||
| 2025-07-29 19:10 |
Foreign Filer Report
Prospectus Filed pursuant to Rule 424(b)(4)
|
English | 36.7 KB | ||
| 2025-07-29 19:07 |
Foreign Filer Report
6-K: Report of foreign issuer
|
English | 654.1 KB | ||
| 2025-07-29 19:07 |
Foreign Filer Report
6-K: Report of foreign issuer
|
English | 36.7 KB | ||
| 2025-07-29 01:15 |
Foreign Filer Report
Other Report or Announcement
|
English | 160.7 KB |
Automate Your Workflow. Get a real-time feed of all Can-Fite BioPharma Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Can-Fite BioPharma Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
